Review
Generic Psychotropic Medications: Issues of Cost-Effectiveness and Patient Benefit
Abstract
Since the implementation of managed care, clinicians have struggled with ways to provide optimal treatment in a cost-effective manner. With the rising cost of medications, generic substitutes appear to be an answer. Some medications have proven to be less effective in generic form. Consumers may be wary of generics. However, when financially motivated, many people choose generic over brand-name products. With the hope of finding effective medications with fewer side effects, drug companies continue to spend money to find the best solutions. Research in medication efficacy is costly, which is handed over to the consumer. Benefits and efficacy of generics will be discussed.This content is limited to qualifying members.
Existing members, please login first
If you have an existing account please login now to access this article or view purchase options.
Purchase only this article ($25)
Create a free account, then purchase this article to download or access it online for 24 hours.
Purchase an SMJ online subscription ($75)
Create a free account, then purchase a subscription to get complete access to all articles for a full year.
Purchase a membership plan (fees vary)
Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.
References
1. Hartman M, Martin A, Nuccio O, et al. Health care spending growth at a historic low in 2008. Health Aff 2010;29:1147-1155.
2. Eli Lilly. Annual report. Available at: http://files.shareholder.com/downloads/LLY/955814689x0x357090/99D528C9-E7DF-48E2-99B0-8D4FA2403BE8/English.PDF. Accessed July 17, 2010.
3. Pfizer, Inc. Financial report. Available at: http://media.pfizer.com/files/annualreport/2009/financial/financial2009.pdf. Accessed July 5, 2010.
4. TEVA Pharmaceutical Industries Limited. Annual report. Available at: http://www.tevapharm.com/financial/reports.asp. Accessed July 17, 2010.
5. Adams CP, Brantner VV. Estimating the cost of new drug development: is it really $802 million?Health Aff 2006;25:420-428.
6. Congressional Budget Office (CBO). Effects of using generic drugs on Medicare's prescription drug spending Available at: http://www.cbo.gov/ftpdocs/118xx/doc11838/Summary_PrescDrug.pdf. Accessed May 28, 2011.
7. Food and Drug Administration. Medicines and you: a guide for older adults. Available at: http://www.fda.gov/Drugs/ResourcesForYou/ucm163959.htm#costs. Accessed December 20, 2010.
8. Tamboli AM, Todkar P, Zope P, et al. An overview on bioequivalence: regulatory consideration for generic drug products. J Bioequiv Availab 2010;2:086-092.
9. Lewek P, Kardas P. Generic drugs: the benefits and risks of making the switch. J Fam Pract 2010;59:634-640.
10. Welage LS, Kirking DM, Ascione FJ, et al. Understanding the scientific issues embedded in the generic drug approval process. J Am Pharm Assoc 2001;41:856-867.
11. Food and Drug Administration. You know that question that goes through your mind when you take your generic drug? Here are the answers. Available at: http://www.fda.gov/Drugs/EmergencyPreparedness/BioterrorismandDrugPreparedness/ucm133809.htm. Accessed March 1, 2011.
12. Ray A, Gulati K. Current trends in pharmacology. New Delhi, India, I. K. International Publishing House Pvt Ltd, 2007.
13. FDA. Orange Book: approved drug products with therapeutic equivalence evaluations. Available at: http://www.accessdata.fda.gov/scripts/cder/ob/default.cfm. Accessed March 25, 2011.
14. Gidal BE, Tomson T. Substitution of generic drugs in epilepsy: is there cause for concern? Epilepsia 2008;49:55-62.
15. Food and Drug Administration. Facts and myths about generic drugs. Available at: http://www.fda.gov/Drugs/ResourcesForYou/Consumers/BuyingUsingMedicineSafely/UnderstandingGenericDrugs/ucm167991.htm. Accessed March 17, 2011.
16. National Alliance on Mental Illness. Commonly prescribed psychotropic medications. Available at: http://www.nami.org/Template.cfm?Section=Policymakers_Toolkit&Template=/ContentManagement/HTMLDisplay.cfm&ContentID=18971. Accessed May 12, 2011.
17. Shah RB, Collier JS, Sayeed VA, et al. Tablet splitting of a narrow therapeutic index drug: a case with levothyroxine sodium. AAPS. PharmSciTech 2010;1-9.
18. Henderson JD, Escham RH. Generic substitution: issues for problematic drugs. South Med J 2001;94:16-21.
19. Buck ML. Amphetamines in the treatment of attention-deficit/hyperactivity disorder. Pediatr Pharm 2002;8:1-6.
20. Croom KF, Plosker GL. Spotlight on the pharmacoeconomics of escitalopram in depression. CNS Drugs 2004;18:469-473.
21. Dunn JD, Cannon E, Mitchell MP, et al. Utilization and drug cost outcomes of a step-therapy edit for generic antidepressants in an HMO in an integrated health system. J Manag Care Pharm 2006;12:294-302.
22. Hollis A. How cheap are Canada's drugs really? J Pharm Pharm Sci 2004;7:215-216.
23. Congressional Budget Office (CBO). How increased competition from generic drugs has affected prices and returns in the pharmaceutical industry. Available at: http://www.cbo.gov/ftpdocs/6xx/doc655/pharm.pdf. Accessed May 28, 2011.
24. Figueiras MJ, Marcelino D, Cortes MA. People's views on the level of agreement of generic medicines for different illnesses. Pharm World Sci 2008;30:590-594.
25. National Center for Biotechnology Information, US National Library of Medicine, National Institutes of Health. Sertraline. In: PubMed Health. Available at: http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0001017. Accessed July 5, 2010.
26. Al-Jazairi AS, Bhareth S, Eqtefan IS, et al. Brand and generic medications: are they interchangeable? Ann Saudi Med 2008;28:33-41.
27. Hassali MA, Shafie AA, Awaisu A, et al. Physicians' views on generic medicines: a narrative review. J Generic Med 2010;730-739.
28. Goldman DP, Joyce GF, Zheng Y. Prescription drug cost sharing: associations with medication and medical utilization and spending and health. JAMA 2007;298:61-69.
29. Odierna DH, Bero LA. Systematic reviews reveal unrepresentative evidence for the development of drug formularies for poor and nonwhite populations. J Clin Epidemiol 2009;62:1268-1278.
30. Jobst BC, Holmes GL. Prescribing antiepileptic drugs: should patients be switched on the basis of cost? CNS Drugs 2004;18:617-628.
31. Ganguli G. Consumers devise drug cost-cutting measures: medical and legal issues to consider. Health Care Manag 2003;22:275-281.
